Altimmune (ALT) Deferred Taxes (2012 - 2025)

Altimmune (ALT) posted quarterly Deferred Taxes of -$681000.0 for Q1 2025, up 92.6% quarter-over-quarter from -$9.2 million in Q4 2018.

Analysis

Altimmune (ALT) Deferred Taxes (2012 - 2025) Analysis & Trends

Altimmune (ALT) has reported Deferred Taxes for 8 consecutive years, with -$681000.0 the latest figure, recorded in Q1 2025.

In Q1 2025, Deferred Taxes changed N/A year-over-year to -$681000.0; the TTM figure through Dec 2025 stood at -$681000.0 (changed N/A YoY), while the FY2025 annual figure was -$681000.0, changed N/A from the prior year.
Deferred Taxes rose to -$681000.0 in Q1 2025 per ALT's latest filing, from -$9.2 million in the prior quarter.
Across five years, Deferred Taxes topped out at -$681000.0 in Q1 2025 and bottomed at -$681000.0 in Q1 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	2.66 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	Altimmune	636.07 Mn	636.07 Mn	-	-

Historic Data

Download Data